Pfizer says it has begun a large-scale study of a pill to prevent COVID-19 infections among people who have been exposed.

The drugmaker announced Monday that the mid-to-late-stage study will test the pill in up to 2,660 healthy participants 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection, Reuters reported.

Pfizer also has started another study of the pill in non-hospitalized, symptomatic adult patients, Reuters reported.

Gilead Sciences Inc’s intravenous drug remdesivir is currently the only approved antiviral treatment for COVID-19 in the U.S.

Did you like this story?
Would you like to receive articles like this in your inbox? Free!

WI Guest Author

This correspondent is a guest contributor to The Washington Informer.

Leave a comment

Your email address will not be published. Required fields are marked *